Guardant Health Investor Presentation
Realizing the $35B+ U.S. opportunity requires delivering the right
information for the right intervention for the right patient population.
U.S. Patient
Population
Advanced-Stage Cancer
~700 K
Cancer Survivors
~15 million
Asymptomatic, Hi-Risk
~35 million
Therapy Selection
Recurrence Monitoring
Screening & Early
Detection
Information
GUARDANT 360 OMN
LUNAR -1
LUNAR-2
Intervention
Targeted & Immuno-
oncology therapies
50+ biopharma companies
Neoadjuvant, Adjuvant, or
Curative or Preventative
Curative
U.S. Market
Size
~$6B
~$15B
~$18B
Source: CDC Statistics; US Census; American Cancer Society, Cancer Facts and Statistics; SEER; Rebecca L. Siegel, Cancer Statistics, 2018, A Cancer Journal for Clinicals, 68:7; Piper
Jaffray, Liquid Biopsy Report, Cowen Equity Research, Foundation Medicine, dated March 18, 2018; CDC, Viral Hepatitis and Liver Cancer report.
Note: Market sizing based on Guardant Health internal analysis.
6
GUARDANT™View entire presentation